Skip to content

Monivent AB – Delårsrapport för andra kvartalet 2024

Stärkt klinisk evidens, ett intensivt regulatoriskt arbete, samt en avsiktsförklaring om att ingå

Published August 26, 2024By

Categorized as Uncategorized

Leave a comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Post navigation

Previous post

Regeringen har tillsatt en ny utredning om carried interest

Next post

Återköp av aktier i Evolution AB (publ)

Finanstidning

Proudly powered by WordPress.